135 related articles for article (PubMed ID: 15178360)
1. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.
Pace CJ; Glick SD; Maisonneuve IM; He LW; Jokiel PA; Kuehne ME; Fleck MW
Eur J Pharmacol; 2004 May; 492(2-3):159-67. PubMed ID: 15178360
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW
Eur J Pharmacol; 2002 Mar; 438(1-2):99-105. PubMed ID: 11906717
[TBL] [Abstract][Full Text] [Related]
3. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats.
Glick SD; Ramirez RL; Livi JM; Maisonneuve IM
Eur J Pharmacol; 2006 May; 537(1-3):94-8. PubMed ID: 16626688
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.
Kuehne ME; He L; Jokiel PA; Pace CJ; Fleck MW; Maisonneuve IM; Glick SD; Bidlack JM
J Med Chem; 2003 Jun; 46(13):2716-30. PubMed ID: 12801235
[TBL] [Abstract][Full Text] [Related]
5. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.
Glick SD; Sell EM; Maisonneuve IM
Eur J Pharmacol; 2008 Dec; 599(1-3):91-5. PubMed ID: 18930043
[TBL] [Abstract][Full Text] [Related]
6. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
Maisonneuve IM; Glick SD
Pharmacol Biochem Behav; 2003 Jun; 75(3):607-18. PubMed ID: 12895678
[TBL] [Abstract][Full Text] [Related]
7. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors.
Glick SD; Maisonneuve IM; Kitchen BA
Eur J Pharmacol; 2002 Jul; 448(2-3):185-91. PubMed ID: 12144940
[TBL] [Abstract][Full Text] [Related]
8. Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?
Taraschenko OD; Panchal V; Maisonneuve IM; Glick SD
Eur J Pharmacol; 2005 Apr; 513(3):207-18. PubMed ID: 15862802
[TBL] [Abstract][Full Text] [Related]
9. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens.
Taraschenko OD; Shulan JM; Maisonneuve IM; Glick SD
Synapse; 2007 Jul; 61(7):547-60. PubMed ID: 17447255
[TBL] [Abstract][Full Text] [Related]
10. Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.
Glick SD; Sell EM; McCallum SE; Maisonneuve IM
Eur J Pharmacol; 2011 Nov; 669(1-3):71-5. PubMed ID: 21871879
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula.
Arias HR; Jin X; Feuerbach D; Drenan RM
Int J Biochem Cell Biol; 2017 Nov; 92():202-209. PubMed ID: 29042244
[TBL] [Abstract][Full Text] [Related]
12. Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
Arias HR; Targowska-Duda KM; Feuerbach D; Jozwiak K
Int J Biochem Cell Biol; 2015 Aug; 65():81-90. PubMed ID: 26022277
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine.
Panchal V; Taraschenko OD; Maisonneuve IM; Glick SD
Eur J Pharmacol; 2005 Nov; 525(1-3):98-104. PubMed ID: 16289028
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine.
Silva EM; Cirne-Santos CC; Frugulhetti IC; Galvão-Castro B; Saraiva EM; Kuehne ME; Bou-Habib DC
Planta Med; 2004 Sep; 70(9):808-12. PubMed ID: 15386189
[TBL] [Abstract][Full Text] [Related]
15. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.
Rho B; Glick SD
Neuroreport; 1998 May; 9(7):1283-5. PubMed ID: 9631413
[TBL] [Abstract][Full Text] [Related]
16. α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo.
McCallum SE; Cowe MA; Lewis SW; Glick SD
Neuropharmacology; 2012 Sep; 63(3):434-40. PubMed ID: 22561751
[TBL] [Abstract][Full Text] [Related]
17. hERG Blockade by Iboga Alkaloids.
Alper K; Bai R; Liu N; Fowler SJ; Huang XP; Priori SG; Ruan Y
Cardiovasc Toxicol; 2016 Jan; 16(1):14-22. PubMed ID: 25636206
[TBL] [Abstract][Full Text] [Related]
18. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.
Glick SD; Kuehne ME; Maisonneuve IM; Bandarage UK; Molinari HH
Brain Res; 1996 May; 719(1-2):29-35. PubMed ID: 8782860
[TBL] [Abstract][Full Text] [Related]
19. Development of novel medications for drug addiction. The legacy of an African shrub.
Glick SD; Maisonneuve IM
Ann N Y Acad Sci; 2000; 909():88-103. PubMed ID: 10911925
[TBL] [Abstract][Full Text] [Related]
20. 18-MC reduces methamphetamine and nicotine self-administration in rats.
Glick SD; Maisonneuve IM; Dickinson HA
Neuroreport; 2000 Jun; 11(9):2013-5. PubMed ID: 10884062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
